Literature DB >> 17724200

Expression of indoleamine 2,3-dioxygenase in human corneal cells as a local immunosuppressive factor.

Yang-Hwan Ryu1, Jae-Chan Kim.   

Abstract

PURPOSE: To identify the localization of indoleamine 2,3-dioxygenase (IDO) in human corneal cells and to evaluate its functional ability as a local immunosuppressive factor.
METHODS: The expression profile of IDO was identified in primary cultures of human corneal cells (fibroblasts, epithelial cells, endothelial cells) by RT-PCR and Western blot analysis. The immunosuppressive function of IDO was assessed by culturing human CD4(+) T cells with conditioned medium derived from the three types of human corneal cells, and changes in proliferation and apoptosis were determined. IDO expression and its apoptotic effects on CD4(+) T cells were also investigated after IFN-gamma treatment.
RESULTS: Among the three types of human corneal cells, IDO mRNA and protein expression were observed in human corneal fibroblasts and epithelial cells, with higher levels in the human corneal fibroblasts. Human CD4(+) T cells cultivated in conditioned medium derived from human corneal fibroblasts showed decreased cell proliferation and increased apoptosis. IFN-gamma treatment significantly induced IDO expression and showed apoptotic effects on immune cells.
CONCLUSIONS: These results suggest that human corneal fibroblasts are relatively immunoresistant and that the IDO expression can act as one of the factors for the maintenance of immune privilege in the cornea.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724200     DOI: 10.1167/iovs.05-1336

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  18 in total

1.  Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.

Authors:  Andrew W Taylor; Henry J Kaplan
Journal:  Ocul Immunol Inflamm       Date:  2010-12       Impact factor: 3.070

2.  Expression of indoleamine 2,3-dioxygenase in a murine model of Aspergillus fumigatus keratitis.

Authors:  Nan Jiang; Gui-Qiu Zhao; Jing Lin; Li-Ting Hu; Cheng-Ye Che; Cui Li; Qian Wang; Qiang Xu; Jie Zhang; Xu-Dong Peng
Journal:  Int J Ophthalmol       Date:  2016-04-18       Impact factor: 1.779

Review 3.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

4.  Immune oppression array elucidating immune escape and survival mechanisms in uveal melanoma.

Authors:  Fang Hou; Qi-Ming Huang; Dan-Ning Hu; Jost B Jonas; Wen-Bin Wei
Journal:  Int J Ophthalmol       Date:  2016-12-18       Impact factor: 1.779

Review 5.  Immunotherapy for uveal melanoma.

Authors:  Dae Won Kim; Jaime Anderson; Sapna P Patel
Journal:  Melanoma Manag       Date:  2016-05-19

Review 6.  Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.

Authors:  Kimberly M Komatsubara; Richard D Carvajal
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

7.  Paradigm shifts in the role of CD4+ T cells in keratoplasty.

Authors:  Khrishen Cunnusamy; Peter W Chen; Jerry Y Niederkorn
Journal:  Discov Med       Date:  2010-11       Impact factor: 2.970

8.  Ocular immune privilege.

Authors:  A W Taylor
Journal:  Eye (Lond)       Date:  2009-01-09       Impact factor: 3.775

9.  Role of NKT cells in anterior chamber-associated immune deviation.

Authors:  Jerry Y Niederkorn
Journal:  Expert Rev Clin Immunol       Date:  2009-03       Impact factor: 4.473

Review 10.  Gene therapy in corneal transplantation.

Authors:  Yureeda Qazi; Pedram Hamrah
Journal:  Semin Ophthalmol       Date:  2013 Sep-Nov       Impact factor: 1.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.